| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Oct 2025 | 22 Sep 2025 |
| Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ending September 30 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on:24.10.2025) | ||
| Board Meeting | 23 Jul 2025 | 23 Jun 2025 |
| Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ending June 30 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 23.07.2025) | ||
| Board Meeting | 9 May 2025 | 21 Mar 2025 |
| Audited Results & Dividend Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 ,inter alia, to consider and approve audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending March 31, 2025 and to recommend final dividend, if any, for the financial year 2024-25 Outcome of Board Meeting Audited Financial results for the quarter and year ended March 31, 2025 (As Per BSE Announcement Dated on: 09/05/2025) | ||
| Board Meeting | 23 Jan 2025 | 23 Dec 2024 |
| DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2024. Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company, at its meeting held on January 23, 2025, has inter alia approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024. (As Per BSE Announcement Dated on: 23/01/2025) | ||
The inspection, conducted between September 4 and September 12, 2025, was a pre-approval review.
Here are some of the stocks that may see significant price movement today: Apollo Hospitals, GMR Airports, RailTel Corporation, etc.
The capital was infused via cash and will be used to support DRL Russia’s working capital requirements.
As per the terms agreement, Alvotech and Dr Reddy’s will jointly develop and manufacture the biosimilar candidate and share costs and responsibilities.
Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.
The board has recommended a final dividend of ₹8 per equity share for FY 2024–25
Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
